Medtronic (Minneapolis) reported FDA approval and U.S. launch of its newest heart devices, the Viva portfolio of cardiac resynchronization therapy with defibrillation (CRT-D) devices and the Evera portfolio of implantable cardioverter-defibrillators (ICD). Read More
